1149. Resistance Analyses of Patient Viral Samples from the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)

BACKGROUND: Remdesivir (RDV) is a broad-spectrum nucleotide analog prodrug approved for the treatment of COVID-19 in non-hospitalized and hospitalized adult as well as pediatric patients with clinical benefit demonstrated in multiple Phase 3 trials. Here we present SARS-CoV-2 resistance analyses fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedskog, Charlotte, Rodriguez, Lauren, Beigel, John H, Dempsey, Walla, Greninger, Alexander L, Roychoudhury, Pavitra, Huang, Meei-Li, Jerome, Keith R, Hao, Linhui, Ireton, Renee, Gale, Michael, Li, Jiani, Perry, Jason, Han, Dong, Camus, Gregory, Porter, Danielle P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752489/
http://dx.doi.org/10.1093/ofid/ofac492.987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752489/
http://dx.doi.org/10.1093/ofid/ofac492.987

Ejemplares similares